In conclusion , the 5-yr results of our randomized study confirm that CMF , particularly when delivered at nearly full doses , can indeed alter the postoperative course of breast cancer with positive axillary nodes .
All our progress reports have consistently demonstrated that there was a significant difference in the relapse-free survival (RFS) favoring patients who received adjuvant CMF .
